Ask AI
ProCE Banner Activity

EV-302/KEYNOTE-A39: Exploratory Analysis of Responders to Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Advanced or Metastatic Urothelial Carcinoma

Conference Coverage
Slideset

This exploratory analysis of the phase III EV-302/KEYNOTE-A39 trial found that enfortumab vedotin plus pembrolizumab improved survival outcomes compared with chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who achieved a response.

Released: June 05, 2025

Expiration: December 04, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Astellas.

Astellas